J Cell Sci 2014
95 percent confidence interval (CI): 0.26, 0.45
A randomized Phase II clinical trial confirmed that the triple therapy combination of an anti-PD-1 antibody (Sintilimab), an HDAC inhibitor (Citarinostat), and an anti-VEGF antibody (Bevacizumab) demonstrated significant clinical efficacy in colorectal cancer
Combining KLOW and GLOW With Other Protocols These peptide blends work powerfully with other optimization protocols
Maximal antioxidant protection was observed only when both antioxidants were simultaneously present, indicating that both antioxidants are needed for cell survival against oxidative stress.
Vickram S, Rohini K, Srinivasan S, Nancy VD, Archana K, Anbarasu K, Jeyanthi P, Thanigaivel S, Gulothungan G, Rajendiran N, Srikumar PS (2021) Role of zinc (Zn) in human reproduction: a journey from initial spermatogenesis to childbirth